{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=16&state=California", "query": { "state": "California", "city": "Sacramento", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 5547, "total_pages": 555, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=17&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=15&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T23:23:45.655Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00584623", "title": "Simultaneous Fluoroscopic and Endoscopic Examination of the Oropharyngeal Phase of Deglutition", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Dysphagia" ], "interventions": [], "intervention_types": [], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2007-03", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-10-27T23:23:45.655Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00584623" }, { "nct_id": "NCT01486927", "title": "An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "rVIII-SingleChain", "type": "BIOLOGICAL" }, { "name": "Octocog alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "12 Years to 65 Years · Male only" }, "enrollment_count": 175, "start_date": "2012-02", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-08-09", "last_synced_at": "2026-10-27T23:23:45.655Z", "location_count": 9, "location_summary": "Sacramento, California • San Diego, California • Aurora, Colorado + 6 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01486927" }, { "nct_id": "NCT01688973", "title": "Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Renal Cell Carcinoma", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer", "Type 1 Papillary Renal Cell Carcinoma", "Type 2 Papillary Renal Cell Carcinoma" ], "interventions": [ { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Tivantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 55, "start_date": "2012-08-20", "completion_date": "2017-04-30", "has_results": true, "last_update_posted_date": "2019-01-03", "last_synced_at": "2026-10-27T23:23:45.655Z", "location_count": 214, "location_summary": "Tucson, Arizona • Anaheim, California • Baldwin Park, California + 154 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01688973" }, { "nct_id": "NCT00148941", "title": "Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tetanus", "Acellular Pertussis", "Diphtheria" ], "interventions": [ { "name": "SB213503 lot 1", "type": "BIOLOGICAL" }, { "name": "SB213503 lot 2", "type": "BIOLOGICAL" }, { "name": "SB213503 lot 3", "type": "BIOLOGICAL" }, { "name": "Infanrix", "type": "BIOLOGICAL" }, { "name": "IPOL", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "4 Years to 6 Years" }, "enrollment_count": 4209, "start_date": "2005-01-06", "completion_date": "2006-12-04", "has_results": true, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-10-27T23:23:45.655Z", "location_count": 24, "location_summary": "Little Rock, Arkansas • Antioch, California • Daly City, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Antioch", "state": "California" }, { "city": "Daly City", "state": "California" }, { "city": "Fairfield", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00148941" }, { "nct_id": "NCT00153803", "title": "Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Non-small Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "Erlotinib (tarceva)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 245, "start_date": "2005-05", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-10-27T23:23:45.655Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00153803" }, { "nct_id": "NCT05334069", "title": "Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Ann Arbor Stage I Lymphoma", "Ann Arbor Stage II Lymphoma", "Ann Arbor Stage III Lymphoma", "Ann Arbor Stage IV Lymphoma", "Chronic Lymphocytic Leukemia", "Chronic Myeloid Leukemia", "Gastroesophageal Junction Adenocarcinoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Invasive Breast Carcinoma", "Kidney Carcinoma", "Malignant Hepatobiliary Neoplasm", "Malignant Solid Neoplasm", "Melanoma", "Muscle-Invasive Bladder Carcinoma", "RISS Stage I Plasma Cell Myeloma", "RISS Stage II Plasma Cell Myeloma", "RISS Stage III Plasma Cell Myeloma", "Sarcoma", "Stage I Bladder Cancer AJCC v6 and v7", "Stage I Breast Cancer AJCC v7", "Stage I Colorectal Cancer AJCC v6 and v7", "Stage I Esophageal Cancer AJCC V7", "Stage I Gastric Cancer AJCC V7", "Stage I Lung Cancer AJCC v7", "Stage I Ovarian Cancer AJCC v6 and v7", "Stage I Pancreatic Cancer AJCC v6 and v7", "Stage I Prostate Cancer AJCC v7", "Stage I Uterine Corpus Cancer AJCC v7", "Stage II Bladder Cancer AJCC v6 and v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage II Colorectal Cancer AJCC v7", "Stage II Esophageal Cancer AJCC v7", "Stage II Gastric Cancer AJCC v7", "Stage II Lung Cancer AJCC v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage II Pancreatic Cancer AJCC v6 and v7", "Stage II Prostate Cancer AJCC v7", "Stage II Uterine Corpus Cancer AJCC v7", "Stage III Bladder Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Esophageal Cancer AJCC v7", "Stage III Gastric Cancer AJCC v7", "Stage III Lung Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage III Prostate Cancer AJCC v7", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IV Bladder Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Esophageal Cancer AJCC v7", "Stage IV Gastric Cancer AJCC v7", "Stage IV Lung Cancer AJCC v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 2000, "start_date": "2022-08-18", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-27T23:23:45.655Z", "location_count": 747, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 502 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05334069" }, { "nct_id": "NCT02816723", "title": "Mindfulness Training in Healthy Older Veterans", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aging" ], "interventions": [ { "name": "Mindfulness-based Stress Reduction", "type": "BEHAVIORAL" }, { "name": "Brain Health", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 60, "start_date": "2016-11-28", "completion_date": "2019-07-31", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-10-27T23:23:45.655Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02816723" }, { "nct_id": "NCT04429542", "title": "Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Squamous Cell Carcinoma of Anal Canal", "Colorectal Cancer", "Squamous Cell Carcinoma of the Lung", "EGFR Amplification", "Epithelial Ovarian Cancer", "Pancreas Cancer", "Cutaneous Squamous Cell Carcinoma", "Head and Neck Neoplasms", "Carcinoma, Squamous Cell", "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "BCA101", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bicara Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 473, "start_date": "2020-06-01", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-27T23:23:45.655Z", "location_count": 15, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04429542" }, { "nct_id": "NCT02158403", "title": "PREVENtion of HeartMate II Pump Thrombosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HeartMate II Pump Thrombosis" ], "interventions": [ { "name": "Clinical Management Recommendations for reducing pump thrombosis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 300, "start_date": "2014-09", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2022-03-25", "last_synced_at": "2026-10-27T23:23:45.655Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 17 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02158403" }, { "nct_id": "NCT03073486", "title": "A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Olumacostat Glasaretil Gel, 5.0%", "type": "DRUG" }, { "name": "Olumacostat Glasaretil Gel, Vehicle", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dermira, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Years", "maximum_age": null, "sex": "ALL", "summary": "9 Years and older" }, "enrollment_count": 744, "start_date": "2017-02-06", "completion_date": "2017-12-21", "has_results": true, "last_update_posted_date": "2021-07-20", "last_synced_at": "2026-10-27T23:23:45.655Z", "location_count": 36, "location_summary": "Guntersville, Alabama • Glendale, Arizona • Bryant, Arkansas + 32 more", "locations": [ { "city": "Guntersville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03073486" } ] }